Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HRS5685 in Healthy Subjects
NCT05328583Phase 1Unknown
- Sponsor
- Retro Biosciences
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of HRS5685 in human immunodeficiency virus type 1 infection (HIV-1) (8 arms), sponsored by Retro Biosciences. Primary endpoint: Incidence and severity of adverse events. Status: unknown.
02
Drugs
HRS5685
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05328583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328583.